

Supplementary Table 2. Disclosure of conflict of interest

All committee members who participated in the development of the guidelines prepared a declaration of interests consisting of the following questions, and information on conflicts of interest within the last three years was as follows.

1. Do you have intellectual property rights such as patents, trademarks, licensing, and royalties in relation to interventions (drugs, medical technologies, etc.) covered by the clinical practice guidelines?
2. Are you employed (if you have an official/informal title) or have you ever been employed by a company or organization that is commercially related to the interventions covered by the clinical practice guidelines (drugs, medical technology, etc.)?
3. Do you have unlisted shares (stock options, non-trading stocks) or listed shares (over 10 million won, including stock options, but excluding indirect investment through mutual funds, etc.) of a company or organization that is commercially related to clinical practice guidelines?
4. Have you ever received research funds, grants, or equipment support from a company or organization that is commercially related to clinical practice guidelines?
5. Have you ever received honoraria, consulting fees, or payments (travel expenses, etc.) exceeding KRW 3 million each year or a total of KRW 10 million or more from companies or organizations that are commercially related to clinical practice guidelines?
6. Do you have any of the relationships described above in your family (parents, spouse, children) or the company in which a family member is involved?

Name	Details
Development Committee	
Seung Up Kim	Participation in research sponsored by Abbvie, Gilead, BMS, EchoSens Medical consultation/lecture fee for BMS, Abbvie, Gilead, Bayer, Eisai, Sirtex, Boston Scientific, Novo Nordisc, Samil, Ildong, Hanmi, Yuhan, Daewoong, Samjin, Chong Kun Dang, Inoen, Pharmaking, GC Wellbeing, GC cell, Acme medical
Mi Na Kim	Nothing to disclose
Beom Kyung Kim	Nothing to disclose
Moon Young Kim	Nothing to disclose
Sang Gyune Kim	Nothing to disclose
Seung-seob Kim	Nothing to disclose
Won Kim	Honoraria/Advisory role: Gilead, Boehringer-Ingelheim, GSK, Novo Nordisk, Samil, Ildong, LG Chemistry, YUHAN, Hanmi, HK Inoen, Standigm, PharmaKing, KOBIO LABS, Olix Pharma, TSD Life Sciences, Daewoong, QUEST, Therasid Bioscience, Korea United Pharm, and Eisai Research funding: GSK, Gilead, Novartis, Pfizer, Roche, Springbank, Altimmune, Ildong, DaeWoong, Dicerna, Celgene, Hanmi, Novo Nordisk, Galmed, Enyo, and KOBIO LABS Stock: KOBIO LABS and Lepidyne Founder: Remedygen Incorporation
Hee Yeon Kim	Nothing to disclose
Yu Rim Shin	Nothing to disclose
Jihyun An	Nothing to disclose
Jung Hwan Yu	Nothing to disclose
Minjong Lee	Nothing to disclose
Eun Joo Lee	Nothing to disclose
Han Ah Lee	Nothing to disclose
Dae Won Jun	Nothing to disclose
Young Eun Chon	Nothing to disclose
Yuri Cho	Nothing to disclose
Eun Ju Cho	Nothing to disclose
Young-Joo Jin	Nothing to disclose
YoungRok Choi	Nothing to disclose
Ji Won Han	Participation in research sponsored by Daewoong, Gilead, and LG Chem

Supplementary Table 2. Continued

Name	Details
Delphi Committee	
Oh Sang Kwon	Nothing to disclose
In Hee Kim	Nothing to disclose
Ji Hoon Kim	Nothing to disclose
Soo Young Park	Nothing to disclose
Byung Kuk Jang	Nothing to disclose
Jae Youn Cheong	Nothing to disclose
Byung Seok Lee	Nothing to disclose
Jung Il Lee	Nothing to disclose
Tae Hee Lee	Nothing to disclose
Hyung Joon Yim	Nothing to disclose
Yong Kyun Cho	Nothing to disclose
Advisory Committee	
Young Seok Kim	Nothing to disclose
Jin Wook Kim	Nothing to disclose
Jong Eun Yeon	Nothing to disclose
Young Suk Lim	Nothing to disclose
Won Young Tak	Nothing to disclose
Moon Seok Choi	Nothing to disclose